CNS Pharmaceuticals Inc. (CNSP)
0.10
0.00 (0.30%)
At close: Jan 28, 2025, 2:51 PM
Company Description
CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors.
The company's lead drug candidate is Berubicin, an anthracycline that is in Phase I and II clinical trials that is used for the treatment of glioblastoma multiforme.
It has license agreements with Houston Pharmaceuticals, Inc. and The University of Texas M.D. Anderson Cancer Center, as well as Animal Life Sciences, LLC; and a development agreement with WPD Pharmaceuticals Inc., as well as a collaboration agreement with Reata Pharmaceuticals, Inc.
The company was incorporated in 2017 and is based in Houston, Texas.
CNS Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Nov 8, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 3 |
| CEO | John Michael Climaco Esq., J.D. |
Contact Details
Address: 2100 West Loop South Houston, Texas United States | |
| Website | https://www.cnspharma.com |
Stock Details
| Ticker Symbol | CNSP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001729427 |
| CUSIP Number | 18978H102 |
| ISIN Number | US18978H2013 |
| Employer ID | 82-2318545 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John Michael Climaco Esq., J.D. | Chief Executive Officer, President & Director |
| Christopher S. Downs CPA, CTP, FP&A | Chief Financial Officer |
| Dr. Donald H. Picker Ph.D. | Chief Science Officer |
| Dr. Sandra L. Silberman M.D., Ph.D. | Chief Medical Officer |
| Dr. Waldemar Priebe Ph.D. | Founder |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 03, 2025 | 8-K | Current Report |
| Dec 11, 2024 | 8-K | Current Report |
| Dec 03, 2024 | 8-K | Current Report |
| Nov 15, 2024 | DEFR14A | Filing |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 01, 2024 | 8-K | Current Report |
| Oct 28, 2024 | DEF 14A | Filing |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 24, 2024 | 424B5 | Filing |